Abstract:Shiyang Wang, 1, 2 Tianlong Wang, 1 Li Wang, 1 Liansheng Zhong, 3 Kai Li 2 1 Department of Geriatric Surgery, The First Hospital, China Medical University, Shenyang 110001, People's Republic of China; 2 Department of Surgical Oncology, The First Hospital, China Medical University, Shenyang 110001, People's Republic of China; 3 Department of Bioinformatics, College of Life Science, China Medical University, Shenyang 110001, People's Republic of China Correspondence: Kai Li Department of Surgical Oncology, The First Hospital, China Medical University, Shenyang 110001, People's Republic of China Tel +86-13998245233 Email cmu_likai@163.com Background: RING finger protein 126 (RNF126), as a novel E3 ubiquitin ligase, plays an oncogenic role in several solid cancers. But its potential role in colorectal cancer (CRC) that harbored 50% mutant p53, to our knowledge, is rarely reported. Materials and Methods: We investigated the clinical significance and relationship of RNF126 and p53 in CRC tissues and cells. Meanwhile, WB, qRT-PCR, co-IP, MTT, and transwell were used to investigate the function and molecular mechanism of RNF126 in regulating malignant biology in vitro. Results: RNF126 was overexpressed in human CRC specimens, which was tightly associated with tumor size ( P =0.021), T stage ( P =0.030), lymph node metastasis ( P =0.006), TNM stage ( P =0.001), and the poor survival ( P =0.003) of CRC patients. RNF126 had no association with p53 mutation in CRC specimens, and in p53 mutant Colo-205 and SW620 cells. However, in p53 wildtype HCT116 and HCT-8 cells, RNF126 silencing upregulated p53 and p21 but inhibited Rb phosphorylation at Serine 780 (pRb), which was inhibited by p53siRNA. Conversely, RNF126 overexpression downregulated p53 and p21 but promoted pRb expression, which was reversed by a classic proteasome inhibitor, MG132. However, the mRNA levels of above target genes were unchanged, implying a ubiquitination dependent post-translational modification involving in above regulation. Meanwhile, RNF126 was co-immunoprecipitated with p53 and p21 to form a triple complex. RNF126 silencing and overexpression inhibited and promoted p53 ubiquitination and degradation in vitro, respectively. In addition, p53siRNA reversed RNF126 silencing-inhibited cell proliferation, drug resistance, and cell mobility in HCT116 cells. Conversely, MG132 inhibited RNF126 overexpression-promoted above cell biology in HCT-8 cells. Conclusion: Overexpression of RNF126 was remarkably associated with multiple advanced clinical characters of CRC patients independent of mutant p53. RNF126 promotes cell proliferation, mobility, and drug resistance in CRC via enhancing p53 ubiquitination and degradation. Keywords: RING finger protein 126, p53, ubiquitination, colorectal cancer

RING-finger protein 6 promotes colorectal tumorigenesis by transcriptionally activating SF3B2

Rnf6 Promotes Colorectal Cancer By Activating The Wnt/Beta-Catenin Pathway Via Ubiquitination Of Tle3

RING-finger protein 6 amplification activates JAK / STAT 3 pathway by modifying SHP-1 ubiquitylation and associates with poor outcome in colorectal cancer Running Title : RNF 6 amplification contributes to CRC by regulating SHP-1

Data from RNF6 Promotes Colorectal Cancer by Activating the Wnt/β-Catenin Pathway via Ubiquitination of TLE3

Supplementary Figures from RING-Finger Protein 6 Amplification Activates JAK/STAT3 Pathway by Modifying SHP-1 Ubiquitylation and Associates with Poor Outcome in Colorectal Cancer

Ring Finger Protein 6 Enhances Chemo-Resistance by Transcriptionally Activating Proliferating Cell Nuclear Antigen Expression and Attenuating DNA Damage in Lung Adenocarcinoma

The E3 Ligase Ring1 Targets P53 For Degradation And Promotes Cancer Cell Proliferation And Survival

RNF183 promotes proliferation and metastasis of colorectal cancer cells via activation of NF- κ B-IL-8 axis

RING Finger 138 Deregulation Distorts NF-кB Signaling and Facilities Colitis Switch to Aggressive Malignancy

SRSF6-regulated Alternative Splicing That Promotes Tumour Progression Offers a Therapy Target for Colorectal Cancer

RNF2 Promotes the Progression of Colon Cancer by Regulating Ubiquitination and Degradation of IRF4.

RNF141 interacts with KRAS to promote colorectal cancer progression

Hnf6 Promotes Tumor Growth In Colorectal Cancer And Enhances Liver Metastasis In Mouse Model

Ring Finger Protein 2 Promotes Colorectal Cancer Progression by Suppressing Early Growth Response 1

&Lt;p>potential Influences of RNF6 on Prognosis and Metastasis of Colorectal Cancer: A Clinical Analysis</p>

RNF6 Promotes Gastric Cancer Progression by Regulating CCNA1/CREBBP Transcription.

The role and mechanism of action of RNF186 in colorectal cancer through negative regulation of NF-κB

RBBP6, a RING Finger-Domain E3 Ubiquitin Ligase, Induces Epithelial–mesenchymal Transition and Promotes Metastasis of Colorectal Cancer

Overexpression of RNF126 Promotes the Development of Colorectal Cancer via Enhancing p53 Ubiquitination and Degradation

Ring Finger Protein 152 Inhibits Colorectal Cancer Cell Growth and is a Novel Prognostic Biomarker.

Ring finger protein 128 promotes, rather than inhibits, colorectal cancer progression by regulating the Hippo signaling pathway